Related Experiment Video
Updated: Jul 13, 2026
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected
Marco Volante1, Silvia Saviozzi, Ida Rapa
1Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Background:
In recent years, molecular insights shed light on the role of the epidermal growth factor receptor (EGFR) in nonsmall cell lung cancer (NSCLC), and new therapeutic agents, such as the EGFR tyrosine kinase inhibitors, were tested successfully, with responsiveness to those agents more likely in those patients with specific EGFR gene alterations. The objective of the current study was to investigate the protein profiles of EGFR, c-erb-B2, transforming growth factor alpha (TGF-alpha) (one of the EGFR ligands commonly expressed in NSCLC), and some downstream molecules, potentially to detect a subset of tumors with an activated autocrine loop that is responsible for higher intracellular signaling.
Methods:
One hundred twelve consecutive patients with resected NSCLC were analyzed by immunohistochemistry for EGFR, the c-erb-B2 receptor, TGF-alpha, and pivotal molecules downstream from EGFR activation. Statistical correlations between the investigated molecular expression profiles and clinicopathologic data were performed.
Results:
EGFR, c-erb-B2, TGF-alpha and downstream molecule expression, per se, was not correlated significantly with any clinicopathologic variables, with the exception of a significant correlation between squamous histology and EGFR and between adenocarcinoma and TGF-alpha. However, nearly 30% of NSCLCs demonstrated coexpression of both TGF-alpha and EGFR, and this molecular status was associated positively with a statistically significant expression of phosphatidylinositol 3 kinase and an inversely with mitogen-activated protein kinase expression.
Conclusions:
The presence of a subgroup of NSCLCs with an activated autocrine loop may help to explain the mechanisms that lead to the relative ineffectiveness of the EGFR tyrosine kinase inhibitor and may support new clinical trials to define whether the subgroup of patients with these tumors reasonably may benefit from higher doses of such inhibitors or from the simultaneous inhibition of EGFR downstream signaling targets.
Insights
Nearly 30% of non-small cell lung cancers (NSCLC) show an activated autocrine loop. This finding may explain why EGFR tyrosine kinase inhibitors are sometimes ineffective and suggests new treatment strategies for NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Epidermal growth factor receptor (EGFR) plays a key role in non-small cell lung cancer (NSCLC).
- EGFR tyrosine kinase inhibitors show success, but patient response varies based on EGFR gene alterations.
- Investigating EGFR ligands and downstream signaling can identify tumors with activated autocrine loops.
Purpose of the Study:
- To investigate protein profiles of EGFR, c-erb-B2, and transforming growth factor alpha (TGF-alpha) in NSCLC.
- To identify downstream molecules involved in EGFR signaling.
- To detect NSCLC subsets with activated autocrine loops driving intracellular signaling.
Main Methods:
- Immunohistochemistry was used to analyze EGFR, c-erb-B2, and TGF-alpha expression in 112 NSCLC patients.
- Expression of downstream molecules linked to EGFR activation was assessed.
- Statistical correlations between molecular profiles and clinicopathologic data were performed.
Main Results:
- EGFR and TGF-alpha expression correlated with squamous histology and adenocarcinoma, respectively.
- Nearly 30% of NSCLCs exhibited coexpression of TGF-alpha and EGFR.
- This coexpression was linked to increased phosphatidylinositol 3 kinase and decreased mitogen-activated protein kinase expression.
Conclusions:
- An activated autocrine loop in a subgroup of NSCLCs may explain the limited efficacy of EGFR tyrosine kinase inhibitors.
- This subgroup may benefit from higher inhibitor doses or combination therapies targeting downstream signaling.
- Further clinical trials are needed to validate treatment strategies for this specific NSCLC subset.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:26Receptor Tyrosine Kinases
01:22Amplifying Signals via Enzymatic Cascade
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:00Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
01:16TGF - β Signaling Pathway